What an ergothioneine review found and where evidence is missing

Editorial study summary

Study type

Systematic review with searches in PubMed, Scopus and Web of Science.

Product relevance

Relevant ingredient evidence synthesis. The review maps studies on ergothioneine and cognition.

Sample or population

19 included studies. The evidence was predominantly preclinical.

Studied dose

Not applicable to the review as a whole.

Duration

Not applicable to the review as a whole.

Finding

The authors identified cognition as an area for further study. The review brings together the existing evidence, much of it from preclinical work.

Limitations

Preclinical findings cannot establish a clinical effect in people. The review does not establish a benefit for a DR.MORGAN formula.

Study quality

The authors assessed included studies using the Office of Health Assessment and Translation (OHAT) risk-of-bias tool.

Funding and disclosures

PubMed lists grants from the Nantong City International Science and Technology Cooperation Program and NeuRG, Faculty of Pharmacy, Universiti Malaya. The authors declared no relevant competing interests.

The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.

Reference

1. The role of Ergothioneine in cognition and age-related neurodegenerative disease: a systematic review. Inflammopharmacology. 2025. DOI 10.1007/s10787-025-01746-6. PMID 40249478